PubMed Health⌕ Search

Biomedical subjects

W H Glinsmann

Publications and source records attributed to W H Glinsmann.

At least 19 recordsLinked to original sources
PubMed1996

Putting things in perspective: building on our experience.

The science and policy underlying food labeling and food fortification have evolved over the past 30 years to a point where dietary guidance and nutrition labeling now provide consumers with highly sophisticated, very specific information about links between diet and health. The focus was once on prevention of nutrient deficiency diseases, but today it is on reducing the risk of chronic diseases and health-related conditions. The Nutrition Labeling and Education Act of 1990, with its provisions for authorization of health claims on food labels, has provided a gateway through which a broader realm of nutrition and health information can be made available to consumers. However, the interpretation and implementation of the health claim provisions must evolve, based on a strong foundation of supporting science, so that industry may more readily make health information available to consumers in a form that is easily understood and effectively used in making their dietary choices. We must develop a database to support claims of beneficial effects of food components. We must be assured that the beneficial effects are not outweighed by safety concerns. And we must develop an environment that is conducive to conducting the research to develop these data. This can only be accomplished through the collaborative efforts of industry, academia, consumers and public health agencies.

Food Labeling↗
PubMed1996

Dietary guidelines for infants: a timely reminder.

The 1995 edition of Dietary Guidelines for Americans has recently been released. In anticipation of the heightened attention that these revised will undoubtedly receive, there is renewed discussion about the need for Dietary Guidelines for Infants. These guidelines would reinforce to parents and nutrition professionals that many diet strategies designed to promote adult health and nutrition are inappropriate for infants and children under the age of two. These guidelines, developed in 1994 by the Gerber Products Company, seek to distinguish the unique dietary needs of this vulnerable population.

Diet↗
PubMed1995

Perspective on the 1986 Food and Drug Administration assessment of the safety of carbohydrate sweeteners: uniform definitions and recommendations for future assessments.

Carbohydrate sweeteners in the diet, which are sources of added sugars, have recently undergone changes that vary considerably among countries. The major driving force for these changes is a technological development that permits conversion of corn and other starches to sweeteners. Major changes in the type of sweeteners used in the United States began in the mid-1970s. In 1986 the US Food and Drug Administration comprehensively evaluated exposures and potential health effects of sugars contained in carbohydrate sweeteners. A UK Department of Health report followed in 1989. An overview of issues is provided, terminologies used to describe sugars and sweeteners are defined, the findings of the US and UK reports are reviewed, trends in the availability of added and naturally occurring sugars are evaluated, and recommendations for future assessment of sugars are discussed. The potential problem of underreporting of food intakes in national food consumption surveys is also reviewed.

Consumer Product Safety↗
PubMed1993

Evidence for success of caloric restriction in weight loss and control. Summary of data from industry.

Data voluntarily supplied by industry were examined to evaluate the success of commercial weight loss programs and products. Information about the safe loss of weight, the maintenance of this lowered weight, and resultant health benefits were reviewed. Information was received from companies that produce over-the-counter preparations designed for persons with a small weight loss goal and from physician-supervised programs for morbidity obese persons placed on very-low-calorie diets. Regardless of the products used, successful weight loss and control was limited and required individualized programs consisting of restricted caloric intake, behavior modification, and exercise. Although some manufacturers of physician-supervised weight loss products for obese persons hav defined the effectiveness of their programs with controlled clinical studies, other industry programs have only begun to accurately assess their effectiveness or safety. Given the importance to public health of reducing obesity, rigorous studies on current weight control practices should be pursued aggressively.

Behavior Therapy↗
PubMed1993

The public health significance of dietary fructose.

It is increasingly appreciated that some foods and food components, including fructose, have specific health benefits and/or potential risks. This recognition is associated with varied health claims and cautionary statements that can drive dynamic changes in food manufacture, selection, consumption, and views about food safety. It is imperative that the scientific and public health communities develop clear standards for evaluating potential benefits and risks, a process for accurately conveying sound public health information to consumers, and a mechanism for monitoring future changes in the food supply and relating these changes to potential health effects. In this paper we discuss specific and general considerations about the health effects of dietary fructose and provide a perspective on their public health significance. On the basis of currently available information, there is little basis for recommending increased or decreased use of fructose in the general food supply or in products for special dietary use.

Dietary Carbohydrates↗
PubMed1992

Fat substitutes: a regulatory perspective.

Fat substitutes, in theory, may provide special health benefits to certain population segments. The most probable benefits are a reduction in total fat intake and a subsequent reduction in intake of calories from fat. Whether individuals who consume high intakes of fat substitutes that are partially or totally nondigestible also benefit from lower calorie intake on a long-term basis is unknown. It is likely that many individuals will compensate by increasing total food intake to maintain calorie intake. Consumption of fat substitutes presents nutrition problems. Those fat substitutes that are partially or totally nondigested may reduce the bioavailability of other nutrients. Similarly, fat substitutes may have adverse effects on normal gastrointestinal tract function or intestinal tract flora. Unlike other functional food additives, fat substitutes can make up a significant portion of the total diet. For this reason, traditional safety factors cannot be applied. Consequently, more reliance on data from clinical studies involving human subjects and requirements for postmarket surveillance will be necessary as part of the approval process.

Dietary Fats↗
PubMed1986

Evaluation of health aspects of sugars contained in carbohydrate sweeteners. Report of Sugars Task Force, 1986.

A critical review composed of two parts: estimates of present levels of sugars intake and of recent trends in nutritive carbohydrate sweetener content of the food supply and a review of recent scientific literature addressing potentially adverse health effects associated with sugars consumption. The review contains an executive summary, an appendix with 75 tables summarizing the estimation of sugars intake of U.S. population groups, and over one thousand citations.

Animals↗
PubMed1983

Effects of chromium supplementation on urinary Cr excretion of human subjects and correlation of Cr excretion with selected clinical parameters.

Daily urinary chromium (Cr) excretion of 15 healthy free-living female subjects was 0.20 +/- 0.03 microgram (mean +/- SEM) and nearly identical for 27 male subjects, 0.17 +/- 0.02 microgram. Minimum Cr absorption calculated from urinary Cr excretion was about 0.4 percent. Increasing intake fivefold by Cr supplementation led to a nearly fivefold increase in Cr excretion suggesting that the extent of absorption of supplemental inorganic chromium was similar to that from normal dietary sources. Correlations between 24-hour Cr excretion and urine volume, age, total creatinine and body weight were not found. Urinary Cr concentration of samples obtained following a morning void correlated with creatinine and Cr concentration following a glucose challenge but not with serum glucose, insulin, lipid parameters, age or body weight. Similar results were obtained for urine samples obtained from subjects during Cr supplementation. These results suggest that urinary Cr excretion does not appear to be a meaningful indicator of Cr status but is a meaningful indicator of Cr intake and that the absorption of supplemental inorganic Cr was similar to that of Cr from normal dietary sources.

Adult↗
PubMed1982

Parenteral galactose therapy in the glucose-intolerant premature infant.

Blood galactose concentrations were measured in 55 neonates consuming at least 80 ml/kg/day of lactose-containing formula. The range of galactose concentration immediately after feeding was 0.8 to 4.2 mg/dl, with a mean of 1.5 +/- 0.2 mg/dl. Galactose concentration fell rapidly after feeding, and normal values for the population fell with a half-life of 45 minutes. Considering galactose as a potential intravenous nutrient, six glucose-intolerant premature infants were given galactose-containing solutions intravenously using a double-blind randomized crossover protocol. Infants were chosen who had sustained hyperglycemia (150 mg/dl) and glucosuria (2+ Clinitest) requiring glucose infusion at a rate below 7 mg/kg/minute for more than 24 hours. Compared to the control glucose period, intravenous alimentation with a solution containing carbohydrate as 50% glucose and 50% galactose resulted in a 65% increase in total carbohydrate infusion rate, normalization of the blood glucose concentration, and decreased glucosuria. Blood galactose concentration averaged 15 mg/dl, and no clinical or biochemical evidence of galactose toxicity was noted.

Blood Glucose↗
PubMed1978

Control of rat skeletal-muscle phosphorylase phosphatase activity by adrenaline.

Administration of adrenaline to an isolated rat hindlimb preparation rapidly decreased muscle phosphorylase phosphatase (EC 3.1.3.17) activity and increased heat-stable and trypsin-labile phosphatase inhibitor activity. This was associated with increased tissue cyclic AMP concentrations, phosphorylase (EC 2.4.1.1) activation and glycogen synthase (EC 2.4.1.11) inactivation.

Animals↗
PubMed1978

Maximizing the purification of the activated glucocorticoid receptor by DNA-cellulose chromatography.

With heat treatment (20 degrees C for 30 min), the glucocorticoid-receptor complex becomes 'activated' and undergoes an increase in affinity for DNA. A two-stage procedure was used to separate sequentially the rat liver glucocorticoid-receptor complex from proteins with high and low affinity for DNA. DNA-cellulose column chromatography of unheated cytosol resulted in the retention of DNA-binding proteins, but not the unactivated receptor complex. Heat treatment of the column eluate resulted in increased affinity of the receptor complex to DNA, and chromatography on DNA-cellulose then yielded receptor complex free from proteins with low affinity for DNA. Removal of DNA-binding proteins during the first chromatographic step was critically dependent on ionic conditions and the ratio of cytosol chromatographed to DNA-cellulose. A purification of 11000-fold (85% yield) was achieved by this procedure. The partially purified receptor complex was taken up by rat liver nuclei.

Animals↗
PubMed1976

Separation and characterization of two phosphorylase phosphatase inhibitors from rabbit skeletal muscle.

Two heat-stable and trypsin-labile inhibitors of phosphorylase phosphatase, designated inhibitor-1 and inhibitor-2, were partially purified from extracts of rabbit skeletal muscle by heating and coloumn chromatography using DEAE-dellulose and Bio-gel P-60. Inhibitor-1 exists in an active phosphorylated form and an inactive dephosphorylated form. The interconversion of phosphorylated inhibitor-1 and dephosphorylated inhibitor-1 is mediated by protein kinase dependent on adenosine 3':5'-monophosphate (cyclic AMP) and a Mn2+-stimulated phosphoprotein phosphatase. Inhibitory activity of inhibitor-2 is not influenced by treatment with either the kinase or the Mn2+-stimulated phosphatase. The molecular weights of inhibitor-1 and inhibitor-2 estimated by sodium dodecylsulfate-polyacrylamide gel electrophoresis are 26000 and 33000 respectively. Both inhibitor-1 and inhibitor-2 inhibit phosphorylase phosphatase by a mechanism which appears to be non-competitive with respect to the substrate phosphorylase a. Inhibitor fractions at early stages of purification also inhibit cyclic-AMP-dependent histone phosphorylation, but this kinase inhibitory activity resides with a protein moiety which is separable from inhibitor-1 and inhibitor-2.

Adenine Nucleotides↗